This study aims to evaluate the feasibility and preliminary effectiveness of a nurse-facilitated interdisciplinary transitional care programme, based on the Omaha system, for Chinese childhood cancer survivors (CCSs) and their parents in Hong Kong. Investigators will conduct a two-arm, randomized waitlist-controlled trial at the Hong Kong Children's Hospital, the only local center for CCS follow-up. Sixty-eight dyads (CCS aged 13-18 and a parent) will be randomized to either the 12-week nurse-led intervention or usual care. The intervention includes an initial face-to-face assessment and regular follow-ups via Zoom, focusing on symptom management, health education, and self-care empowerment, with referrals to other professionals as needed. The control group receives standard discharge care and educational materials, and will be offered the intervention after data collection. Outcomes will be assessed at baseline, and 3 and 6 months post-intervention, including symptom management, quality of life, caregiver burden, self-efficacy, and emergency department visits. Feasibility will be evaluated by recruitment, retention, attendance, and data completeness rates. If effective, this programme could improve transitional care and symptom management for CCSs and their families, and inform clinical practice and policy in Hong Kong and beyond.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Screening rate
Timeframe: Baseline
Eligibility rate
Timeframe: Baseline
Recruitment rate
Timeframe: Baseline
Randomization rate
Timeframe: Baseline
Intervention attendance rate
Timeframe: Immediately after the intervention completion
Retention rate
Timeframe: Baseline, immediately after the intervention completion, 3 months after intervention completion, 6 months after intervention completion
Completion rate
Timeframe: Baseline, immediately after the intervention completion, 3 months after the intervention completion, 6 months after the intervention completion
Missing data
Timeframe: Baseline, immediately after the intervention completion, 3 months after the intervention completion, 6 months after the intervention completion
Adverse events
Timeframe: During the study period including 12-week intervention and 6 months follow-up